Subtitles are available in English and other languages. They are automatically generated using AI, so some errors may occur.
LDL-C management: should it begin in the cathlab?
Sponsored by Amgen
Other coronary interventions
Symposium
Imaging
Amgen
Room 252A
Watch this session if you want
- To discuss the latest evidence on PCSK9 inhibition in patients undergoing elective PCI and its implications for clinical practice
- To assess current and emerging data supporting early and intensive LDL-C management in ACS
- To examine how advanced imaging and artificial intelligence-enabled platforms, including HeartFlow, can enhance early risk stratification and optimise management of high-risk ASCVD
